BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21503784)

  • 1. [Cutaneous side effects of medical tumor therapy].
    Degen A; Alter M; Schenck F; Kapp A; Gutzmer R
    Hautarzt; 2011 Jun; 62(6):444-50. PubMed ID: 21503784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
    Lacouture M; Sibaud V
    Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug reactions caused by chemotherapy agents].
    Ehmann LM; Schrumpf H; Gerber PA; Homey B
    Hautarzt; 2014 May; 65(5):443-9. PubMed ID: 24820802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
    Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
    Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
    Reyes-Habito CM; Roh EK
    J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin toxicity of anti-cancer therapy.
    Ulrich J; Hartmann JT; Dörr W; Ugurel S
    J Dtsch Dermatol Ges; 2008 Nov; 6(11):959-77. PubMed ID: 18992037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
    Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of cutaneous toxicities of targeted therapies.
    Robert C; Sibaud V; Mateus C; Cherpelis BS
    Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Skin manifestations of new targeted treatments].
    Hello M; Barbarot S; Connault J
    Rev Med Interne; 2012 May; 33(5):273-8. PubMed ID: 22385684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
    Ehmann LM; Heinemann V; Wollenberg A
    Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].
    Kähler KC; Hauschild A
    Hautarzt; 2009 May; 60(5):433-40. PubMed ID: 19430753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients.
    Chularojanamontri L; Tuchinda P; Likitwattananurak C; Pongparit K; Rujitharanawong C; Ithimakin S; Kulthanan K
    Asian Pac J Allergy Immunol; 2019 Mar; 37(1):12-18. PubMed ID: 29549700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
    Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
    Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cutaneous side effects of targeted cancer drugs].
    Below J; Homey B; Gerber PA
    Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous reactions to molecular targeted therapies].
    Pföhler C; Ugurel S
    Hautarzt; 2008 Oct; 59(10):814-20. PubMed ID: 18766322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.